Geode Capital Management LLC grew its position in shares of Glaukos Corp (NYSE:GKOS) by 14.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 365,226 shares of the medical instruments supplier’s stock after purchasing an additional 44,867 shares during the quarter. Geode Capital Management LLC owned 1.05% of Glaukos worth $20,513,000 as of its most recent filing with the SEC.
Several other hedge funds have also recently modified their holdings of GKOS. Victory Capital Management Inc. bought a new stake in shares of Glaukos during the 4th quarter worth $20,893,000. New York State Common Retirement Fund boosted its position in shares of Glaukos by 139.3% in the fourth quarter. New York State Common Retirement Fund now owns 510,458 shares of the medical instruments supplier’s stock worth $28,672,000 after buying an additional 297,158 shares during the period. FMR LLC boosted its position in shares of Glaukos by 16.2% in the third quarter. FMR LLC now owns 1,227,430 shares of the medical instruments supplier’s stock worth $79,660,000 after buying an additional 171,268 shares during the period. BlackRock Inc. boosted its position in shares of Glaukos by 6.3% in the fourth quarter. BlackRock Inc. now owns 2,563,895 shares of the medical instruments supplier’s stock worth $144,014,000 after buying an additional 151,304 shares during the period. Finally, Morgan Stanley boosted its position in shares of Glaukos by 180.5% in the third quarter. Morgan Stanley now owns 213,446 shares of the medical instruments supplier’s stock worth $13,851,000 after buying an additional 137,358 shares during the period.
Shares of Glaukos stock traded up $1.92 during trading on Friday, reaching $73.30. The company’s stock had a trading volume of 275,915 shares, compared to its average volume of 382,277. The firm has a market capitalization of $2.61 billion, a PE ratio of -198.11 and a beta of 1.63. Glaukos Corp has a one year low of $31.09 and a one year high of $83.14.
Several analysts have recently commented on GKOS shares. Stifel Nicolaus raised their target price on Glaukos from $58.00 to $68.00 and gave the stock a “positive” rating in a research report on Thursday, February 28th. Stephens raised their target price on Glaukos from $70.00 to $80.00 and gave the stock an “overweight” rating in a research report on Thursday, February 28th. Wells Fargo & Co reaffirmed a “buy” rating on shares of Glaukos in a research report on Wednesday, March 20th. BTIG Research assumed coverage on Glaukos in a report on Friday, March 8th. They set a “neutral” rating and a $66.02 price objective for the company. Finally, Piper Jaffray Companies reiterated an “overweight” rating and set a $80.00 price objective on shares of Glaukos in a report on Thursday, February 28th. Four equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $71.34.
In related news, CFO Joseph E. Gilliam sold 5,000 shares of Glaukos stock in a transaction dated Tuesday, February 19th. The stock was sold at an average price of $70.03, for a total transaction of $350,150.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Chris M. Calcaterra sold 90,000 shares of Glaukos stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $67.69, for a total value of $6,092,100.00. Following the sale, the chief operating officer now directly owns 193,344 shares in the company, valued at $13,087,455.36. The disclosure for this sale can be found here. Insiders own 11.60% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece of content was published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.baseballdailydigest.com/news/2019/04/26/geode-capital-management-llc-acquires-44867-shares-of-glaukos-corp-gkos.html.
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery.
Recommended Story: When is a capital gain realized?
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.